

Supplementary Materials:

Supplementary Table S1. Demographic and endo-metabolic data in patients presenting with diencephalic syndrome vs those without diencephalic syndrome.

Factors and categories	Diencephalic Syndrome		<i>p</i> value
	Yes n=27	No n=63	
AT DIAGNOSIS			
Gender male	10 (37.0)	32 (50.8)	0.231
Age (years)	0.84 [0.50 – 1.90] (0.25-2.90)	2.00[1.20 – 2.60] (0.06-3.00)	<0.0001
Age ≤1 year	18 (66.7)	12 (19)	<0.0001
NF1	1 (3.7)	26 (41.3)	<0.0001
Radiological Classification			
MDC 1	0 (0)	19 (30.2)	0.001
MDC 2	4 (14.8)	21 (33.3)	0.072
MDC 3/4	23 (85.2)	23 (36.5)	<0.0001
Hypothalamic involvement	27 (100)	29 (46)	<0.0001
Leptomeningeal Metastases	9 (33.3)	2 (3.2)	<0.0001
Visual symptoms at diagnosis	12 (44.4)	29 (46)	0.890
Raised intracranial pressure at diagnosis	10 (37)	12 (19)	0.069
AT LATEST FOLLOW UP			
Presence of endo-metabolic disorders	23 (85.2)	29 (46)	0.001
M-EMS(score 0-10)	2 [1 – 5] (0 – 7)	0 [0 – 3] (0 – 7)	0.002
APD	21 (77.8)	26 (41.3)	0.001
GHD*	16 (59.3)	21 (33.3)	0.022
TSHD*	11 (40.7)	10 (15.9)	0.011
ACTHD*	9 (33.3)	10 (15.9)	0.063
CPP*	14 (51.9)	10 (15.9)	<0.0001
GnD*	8 (29.6)	9 (14.3)	0.088
PPD	6 (22.2)	9 (14.3)	0.355
CDI*	2 (7.4)	6 (9.5)	1.000
SIADH*	4 (14.8)	6 (9.5)	0.479
CSWS*	1 (3.7)	0 (0)	
MD	11 (40.7)	12 (19)	0.031
Obesity*	11 (40.7)	12 (19)	0.031
IGT/T2DM*	4 (14.8)	7 (11.1)	0.623
Follow-up time (years)	9.3 [3.6 – 15] (1.13-21.74)	9.9 [4 – 11.9] (0.52-25)	0.812
Deceased	5 (18.5)	4 (6.3)	0.121

Categorical variables are reported as number and percentage. Continuous nonparametric variables are presented as median [interquartile range] (range).

*Items of the Modified Endocrine Morbidity Score (M-EMS)

M-EMS: Modified Endocrine Morbidity Score; APD: Anterior Pituitary Dysfunction; GHD; Growth Hormone Deficiency; TSHD: TSH Deficiency; ACTHD: ACTH Deficiency; CPP: Central Precocious Puberty; GnD: Gonadotropin Deficiency; PPD: Posterior Pituitary Dysfunction; CDI: Central Diabetes Insipidus;

SIADH: Syndrome of Inappropriate Secretion for ADH; CSWS: Cerebral Salt Wasting Syndrome; IGT: Impaired Glucose Tolerance, T2DM: Type 2 Diabetes Mellitus.